The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.h

Nontuberculous pulmonary mycobacterial infection/superinfection

Publications

Hazara AM, Edey M, Roy A, Bhandari S

Rapidly growing non-tuberculous mycobacterial infection in a renal transplant patient after alemtuzumab induction.

Transplant infectious disease : an official journal of the Transplantation Society. 2014;16(5):847-52

Saadeh CE, Srkalovic G

Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.

Pharmacotherapy. 2008;28(2):281-4

Abad S, Gyan E, Moachon L, Bouscary D, Sicard D, Dreyfus F, Blanche P

Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;37(2):e27-8